Warberg Asset Management’s Rein Therapeutics RNTX Stock Holding History

Warberg Asset Management’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$101K	Buy	+99,000	New	+$120K	0.02%	138
2025 Q4	–	Sell	-11,000	Closed	-$12.6K	–	229
2025 Q3	$12.6K	Buy	+11,000	New	+$14K	﹤0.01%	166
2024 Q4	–	Sell	-10,000	Closed	-$35.4K	–	239
2024 Q3	$35.4K	Sell	10,000 -21,354	-68%	-$57.1K	0.01%	146
2024 Q2	$86.2K	Buy	+31,354	New	+$129K	0.01%	138

Other funds holding RNTX

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Warberg Asset Management's RNTX Position: Q2 2026 in Review

Warberg Asset Management opened a new position in Rein Therapeutics (RNTX) in Q2 2026: 99,000 shares worth $101K. The stake represents 0.02% of the portfolio and ranks #138 among its holdings. This is a return to the name: Warberg Asset Management previously reported a position in RNTX as recently as Q3 2025.

Warberg Asset Management first reported a position in RNTX in Q2 2024 and has held it in 4 quarters since. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

Warberg Asset Management held 99,000 shares of Rein Therapeutics worth $101K as of Q2 2026.
Rein Therapeutics was a new Warberg Asset Management position in Q2 2026.
Rein Therapeutics made up 0.02% of Warberg Asset Management's portfolio in Q2 2026, its #138 holding.
Warberg Asset Management first reported a position in Rein Therapeutics in Q2 2024 and has held it in 4 quarters since.
60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Warberg Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.